Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Macrogenics (MGNX)

Macrogenics (MGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Macrogenics 9704 MEDICAL CENTER DRIVE Rockville MD 20850 USA

www.macrogenics.com P: 301-251-5172 F: 301-251-5321

Description:

MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 952,178
Enterprise Value, $K 851,218
Shares Outstanding, K 62,561
Annual Sales, $ 58,750 K
Annual Net Income, $ -9,060 K
Last Quarter Sales, $ 10,720 K
Last Quarter Net Income, $ -46,070 K
EBIT, $ -168,240 K
EBITDA, $ -163,600 K
60-Month Beta 2.09
% of Insider Shareholders 11.30%
% of Institutional Shareholders 96.89%
Float, K 55,492
% Float 88.70%
Short Volume Ratio 0.46

Growth:

1-Year Return 123.49%
3-Year Return -52.17%
5-Year Return -12.63%
5-Year Revenue Growth -2.28%
5-Year Earnings Growth 50.36%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.75 on 03/07/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -2.24
EPS Growth vs. Prev Qtr -44.23%
EPS Growth vs. Prev Year -457.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MGNX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -88.49%
Return-on-Assets % -43.12%
Profit Margin % -15.42%
Debt/Equity 0.00
Price/Sales 16.56
Price/Cash Flow N/A
Price/Book 6.01
Book Value/Share 2.46
Interest Coverage -5.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar